Journal of Andrology Download to Citation Manager
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oesterling, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oesterling, J. E.

Journal of Andrology, Vol 12, Issue 6 348-355, Copyright © 1991 by The American Society of Andrology

REVIEW

The origin and development of benign prostatic hyperplasia. An age-dependent process

J. E. Oesterling
Department of Urology, Mayo Clinic, Rochester, Minnesota 55905.

Although the exact cause of benign prostatic hyperplasia (BPH) is not well defined, it is thought to occur as the result of epithelial-stromal interactions in the appropriate hormonal milieu. Benign prostatic hyperplasia originates in the periurethral and transition zones of the prostate in a microscopic (histologically identifiable) state as early as the third decade of life. With advancing age and the presence of androgens, approximately 50% of microscopic BPH will develop into macroscopic (palpably enlarged prostate) BPH. However, clinically significant BPH necessitating treatment will develop in only 50% of men with an enlarged prostate gland. In the United States, the estimated risk of a 50-year-old man undergoing a prostatectomy in his lifetime is approximately 25% to 40%. If left untreated, a significant number of symptomatic patients will remain stable or improve without adverse sequelae.


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S.-P. Huang, W.-J. Wu, W.-S. W. Chang, M.-T. Wu, Y.-Y. Chen, Y.-J. Chen, C.-C. Yu, T. T. Wu, Y.-H. Lee, J.-K. Huang, et al.
p53 Codon 72 and p21 Codon 31 Polymorphisms in Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2217 - 2224.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by The American Society of Andrology.